27O Long-term survival outcomes and immune subgroup analyses in the COLIBRI study: Induction nivolumab plus ipilimumab with immunotherapy maintenance (ICB) prior to and following chemoradiation (RT-CT) in locally advanced cervical cancer (LACC)

ESMO Open 2026 Open access

Read full text
Authors: F. Joly Lobbedez, D. Bello Roufai, A-C. Hardy-Bessard, A. DeMontfort, A-M. Savoye, S. Betrian, M-C. Kaminsky-Forrett, F. Lecuru, Y. Fernandez Diez, L. Gladieff, F. Cherifi, I. Treilleux
+8 more A. Lainé, C. Caux, B. Dubois, P. Saintigny, R. Ohkuma, L. Michon, A. Angelergues, I.L. Ray-Coquard
DOI: 10.1016/j.esmoop.2026.108053
Cited by: 1

Abstract

Induction nivolumab plus ipilimumab associated with RT-CT is a promising treatment intensification strategy (Ray-Coquard et al., Nature Comm 2026) in LACC. Although immune modulation and early tumor responses have been previously reported, there is less information on survival outcomes and their relation to baseline immune parameters. Here we report the final survival outcomes of the multicenter single arm COLIBRI study, including exploratory immuno-based subgroup analyses.

Fields of Study & Subjects

Cancer Immunotherapy and Biomarkers Endometrial and Cervical Cancer Treatments Immunotherapy and Immune Responses

Publication details

Journal / source
ESMO Open
Publisher
Elsevier BV
Volume
11
Pages
108053–108053
Publication date
1 July 2026
Language
EN